Related Experiment Videos

[Acquisition of resistance to anticancer agents by overproduction of target enzymes]

M Inaba1

  • 1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.

Insights

Anticancer drug resistance in cancer cells is often caused by overproducing target enzymes like dihydrofolate reductase. Gene amplification in chromosomes explains this common resistance mechanism.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Context:

  • Antimetabolic anticancer agents target specific enzymes crucial for cancer cell proliferation.
  • Acquired resistance to these drugs is a significant clinical challenge.
  • Understanding resistance mechanisms is vital for developing effective cancer therapies.

Purpose:

  • To investigate the common mechanisms of acquired resistance to antimetabolic anticancer agents.
  • To explore the role of target enzyme overproduction and gene amplification in drug resistance.
  • To analyze the relationship between drug resistance levels, enzyme activity, and gene expression.

Summary:

  • Antimetabolic anticancer drugs, including methotrexate and 5-fluorouracil, target specific enzymes such as dihydrofolate reductase and thymidylate synthase.
  • Overproduction of these target enzymes is a frequently observed mechanism in drug-resistant cancer cell lines.
  • Gene amplification, leading to increased enzyme levels, is often found in resistant cells, residing in double minute chromosomes or homogeneously stained regions.

Impact:

  • This study highlights a common molecular mechanism underlying resistance to a class of anticancer drugs.
  • Findings suggest that targeting enzyme overproduction or gene amplification could be potential therapeutic strategies.
  • The research provides a foundation for further investigation into overcoming drug resistance in cancer treatment.

Related Concept Videos